- $289.46bn
- $331.15bn
- $56.33bn
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
Brief: Novartis Receives European Commission Approval For Cosentyx
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant
Corrected: TABLE-Swiss trade surplus at CHF 4.35 bln in August (Sept. 17)
Table: Swiss trade surplus at CHF 1.31 bln in September
Factbox: Major drugmakers turn to China for licensing deals
Novartis ends mid-stage Fabhalta trial targeting serious kidney condition (updated)
Swiss stocks - Factors to watch on October 19
Novartis ends mid-stage Fabhalta trial targeting serious kidney condition
China biotech's ingenuity extends to dealmaking
China biotech's ingenuity extends to dealmaking
Factbox: Major drugmakers turn to China for licensing deals
Atrium Therapeutics rallies after $50 mln equity raise
US FDA expands use of Novartis drug for chronic skin condition
Brief: Novartis Says FDA Approves Rhapsido (Remibrutinib) As First Treatment For Symptomatic Dermographism
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Factbox: Global healthcare companies invest billions to boost US presence
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions